1-10 of 551
Post: Parker Institute to Share Pancreatic Cancer Trial Results, Microbiome and Immunotherapy Research, and New CAR-T Approaches at AACR 2019
SAN FRANCISCO – March 20, 2019 – Just months after the first Nobel Prize for cancer immunotherapy was awarded, Parker Institute...
Post: Carl June, MD: How He Developed CAR-T and Reflections on Cell Therapy
Interviewed by Lily Oncology’s Kim Blackwell, MD, Parker Institute director Carl June, MD, recalls breakthrough moments in his career that led...
Post: From Bench to Bedside: Dr. Padmanee Sharma Talks Biomarkers, Broken Arms and Being the Nobelle of the Ball
A Q&A with One of Cancer Immunotherapy’s Leading Minds When she was 7 years old, Padmanee “Pam” Sharma ended up in...
Post: A Single Dose of a PD-1 Inhibitor Before Surgery May Predict Outcomes in Patients With Melanoma
A single dose of a programmed cell death protein 1 (PD-1) inhibitor before resection for melanoma may predict clinical outcomes for...
Post: A New Wave of Clinical Trials in Immuno-Oncology: Collaborative Group Trials
Panelists: Theresa LaVallee, PhD, Vice President, Translational Medicine and Regulatory Affairs, Parker Institute for Cancer Immunotherapy Kim Blackwell, MD, Vice President...
Post: PICI President and CEO Jeffrey Bluestone To Be Honored with the AACR-Irving Weinstein Foundation Distinguished Lectureship
The American Association for Cancer Research (AACR) announced today that Jeffrey Bluestone, PhD, Parker Institute for Cancer Immunotherapy president and CEO,...
Post: High-Fiber Diet May Help Gut ‘Microbiome’ Battle Melanoma
A healthy diet may trigger a better response to a certain kind of melanoma treatment. How? New research suggests that a...